On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
According to the Federal Reserve’s 2023 Economic Well-Being of U.S. Households study, many Americans feel financial uncertainty, but a surprising 31% of Americans report having no financial concerns. However, the detailed study released in May 2024 paints a concerning picture of Americans’ financial well-being. While 72% of respondents reported they were at least doing OK financially, this is a decrease from 73% in 2022 and a significant drop from the post-pandemic high of 78% in 2021. This mark
The United States Supreme Court is expected to issue a ruling at any time on whether the principle of presidential immunity protects former President Donald Trump from prosecution in the federal election interference case brought by special counsel Jack Smith.